NUWAY III

NUWAY III is a SAMHSA-registered addiction-treatment facility located at Minneapolis, MN. The facility offers specific levels of care: Inpatient, Dual Dx. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at NUWAY III

Level-of-care documentation: The facility's documented care levels are The facility offers specific levels of care: Inpatient, Dual Dx. — each of which is appropriate for specific clinical presentations. Matching the level to the specific clinical need is the pre-admission work. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

NUWAY III accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The operational prerequisite for admission is written documentation of: (a) network contract status; (b) prior authorization; (c) cost-sharing structure; (d) medical-necessity criteria applied. Absence of any of these four increases the probability of post-admission financial disagreement.

Specialty programming

The facility's documented specialty programming includes: Adult men, Clients with co-occurring mental and substance use disorders, Clients who have experienced trauma. Clinical verification of specialty programming should encompass credentialed staff profile, programming-hour documentation, and specialty-specific medical-necessity documentation for third-party authorization. The MHPAEA 2024 rule addresses specialty-program network adequacy for patients requiring specific clinical capabilities.

Before you call

Operational admission checklist for NUWAY III: (a) clinical assessment with documented ASAM 4e level-of-care recommendation; (b) insurance benefits verification in writing; (c) MAT policy documentation; (d) accreditation and licensure verification; (e) confirmed prior authorization for specific level of care. Each should be obtained in written form prior to admission. If the clinical situation involves opioid use disorder, confirm explicitly whether NUWAY III offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.